Pallas - P95 Netherlands

Name

Pallas - P95 Netherlands

Legal name

P95 CVBA

Website

https://pallashrc.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Contract research organization
• Clinical trial services
• Vaccine development research
• Real-world evidence studies
• Epidemiology consulting

Headquarters

HQ city

Leuven

HQ country

Belgium

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. CRO Clinical Trial Services: Full-service contract research organization providing clinical trial services for vaccines and infectious diseases across Phase I-IV, including study design, site identification, trial management, safety management, data analysis, and medical writing
2. Epidemiology and RWE Studies: Real-world evidence generation and epidemiological research services including non-interventional studies, disease burden analysis, vaccine effectiveness studies, and healthcare resource utilization analysis
3. Pharmacovigilance Services: Safety management and regulatory compliance services for clinical trials and marketed vaccines
4. Data Management and Biostatistics: Data management, biostatistics, statistical programming, and reporting services for clinical and epidemiological studies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

P95 is a full-service Contract Research Organization (CRO) that designs, manages, and executes Phase I-IV clinical trials for vaccines and infectious diseases, alongside epidemiology studies and real-world evidence generation. The company delivers end-to-end services including study design, site identification, trial management, safety/pharmacovigilance management, data management, biostatistics, and medical writing for vaccine manufacturers, pharmaceutical companies, biotech firms, and public health agencies globally.

Product overview

P95 is a full-service Contract Research Organization (CRO) specializing in complex clinical development and real-world evidence solutions. The company offers an integrated portfolio of services spanning Clinical Trial Delivery, Epidemiology and Real-World Evidence Solutions, Africa and LMICs Services, and Data, Analysis, Safety and Writing. Through strategic acquisitions, P95 has incorporated specialized capabilities from Assign DMB (data management and biometrics), 4Clinics (biometrics and medical writing), Pallas Health Research (epidemiology and public health), and OnQ Research (African clinical trials). The combined organization delivers clinical development and RWE programs across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Delivery
• Epidemiology and Real-World Evidence (RWE) Solutions
• Africa and LMICs Services
• Data, Analysis, Safety and Writing

Quantifiable outcome

• 1,000+ clinical trials Phase I-IV completed
• +3 more outcomes

Named customers13 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Partnerships

Eight partnerships are on record, tiered major and core.

• LatinaBAmajorStrategic or Co-development Partner · 29 January 2025Strategic partnership with LatinaBA, a regional CRO with 15+ years conducting clinical trials in Latin America. Collaboration enhances execution of clinical and epidemiological trials across Latin America, extending reach to additional countries in the region.
• CEPI Enable Programme PartnerscoreStrategic or Co-development Partner · 28 July 2021P95 serves as coordinating institution for CEPI's Enable programme, the largest-ever Lassa fever epidemiological study. In-country partners include FORS (Benin), Phebe Hospital/NPHIL (Liberia), Kenema Government Hospital/Tulane University (Sierra Leone), and Université Gamal Nasser de Conakry/RKI (Guinea). CEPI provided US$10.3 million in funding.
• COVIDRIVE Consortium PartnerscoreStrategic or Co-development Partner · 22 July 2021Public-private partnership evaluating brand-specific COVID-19 vaccine effectiveness in Europe. Partners include: FISABIO (Spain), THL (Finland), AstraZeneca, CureVac, Janssen, Sanofi-Pasteur, and GSK. Leverages existing influenza vaccine effectiveness platform (DRIVE) endorsed by EMA since 2017.
• Julius ClinicalcoreStrategic or Co-development PartnerMerger completed November 2025 creating 500+ person global CRO with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. Combined organization delivers clinical development and RWE programs across five continents.
• OnQ ResearchcoreStrategic or Co-development PartnerMerger completed 2022-2023, bringing OnQ Research's African clinical trial expertise and operational excellence into P95. OnQ had conducted 500+ clinical trials across 10+ African countries.
• Assign DMBmajorStrategic or Co-development PartnerAcquisition completed September 2024, expanding data management and biostatistics services. Assign DMB, founded in 2005, is a leading Austrian CRO with expertise in clinical data management and biometrics for infectious diseases and vaccines.
• 4ClinicsmajorStrategic or Co-development PartnerAcquisition completed July 2024, strengthening biometrics, medical writing, regulatory affairs, and clinical operations. 4Clinics has offices in Belgium, France, and Morocco with expertise in vaccines, immunotherapeutics, and medical devices.
• Pallas Health Research and ConsultancymajorStrategic or Co-development PartnerAcquisition completed 2021, bringing Dutch epidemiology and public health expertise. Pallas specialized in systematic literature reviews, RWE studies, health technology assessment, and healthcare policy for EFSA, ECDC, RIVM, ZonMw, and Dutch Ministry of Health.

Scale indicators7 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Worldwide Clinical Trials: Mid-sized global CRO with therapeutic specialty areas including infectious diseases and vaccines. Closely matches P95's positioning as a science-led CRO serving complex indications.
• Nexelis: Vaccine and infectious-disease specialty CRO with laboratories and clinical trial services, directly comparable to P95's therapeutic focus. Closely related via former Nexelis CEO Benoit Bouche, now P95's Chairman.
• Precision for Medicine: Specialty CRO focused on biomarker-driven trials, oncology, rare disease, and increasingly infectious diseases. Direct therapeutic-area overlap with P95's vaccine and infectious disease franchise.

Broad incumbents

• Charles River Laboratories: Established CRO/preclinical services provider with vaccine and infectious disease capabilities through its Research Models and Biologics segments. Competes for large vaccine development contracts alongside P95.
• Syneos Health: Large biopharmaceutical solutions organization offering clinical development and commercialization services. Competes with P95 across vaccines and infectious disease trials at greater scale.
• ICON plc: Global full-service CRO providing Phase I-IV clinical trial services across all major therapeutic areas, including vaccines and infectious diseases. Directly competes with P95 for large pharma trial awards but at substantially greater scale.
• IQVIA: World's largest CRO with comprehensive clinical development, real-world evidence, and technology platforms. Overlaps with P95 across vaccines, RWE, and Phase I-IV execution, and competes for both enterprise and biotech sponsors.
• Parexel International: Large global CRO with broad Phase I-IV capabilities across multiple therapeutic areas including infectious diseases. Overlaps with P95 on biopharma clinical trial services and competes for mid-to-large pharma contracts.
• Medpace Holdings: Mid-to-large CRO with full-service clinical development across multiple therapeutic areas. Competes with P95 for mid-sized biopharma trial work but operates at larger scale.

Emerging players

• Clinerion: Real-world evidence and clinical trial enablement platform focused on accelerating patient recruitment and data-driven trial design. Overlaps with P95's RWE and patient/site enablement offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@p95/videos
• LinkedInlinkedin.com/company/pallasp95netherlands

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pallas - P95 Netherlands